Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05491083 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Study acronym: ComPACT
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 31, 2022 to Jun 12, 2023
    • Study sites: 0 to 1
    v3
  3. Start date: Oct 1, 2022 to Dec 31, 2022
    • Primary completion date: Oct 1, 2025 to Dec 31, 2025
    • Study completion date: Oct 1, 2026 to Dec 31, 2026
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase Ib followed by phase II clinical trial evaluating the safety and efficacy of combination of ADG106 with pembrolizumab in patients with metastatic cancers. The Phase Ib dose finding part will include all solid tumor subtypes with treatment refractory disease, while phase II will focus on only patients with TNBC.
Trial Details
NCT Number NCT05491083
Lead Sponsor National University Hospital, Singapore
Collaborators: Adagene Inc, Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Advanced Solid Tumor, Triple Negative Breast Cancer
Related terms Breast Neoplasms, Triple Negative Breast Neoplasms
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov